» Articles » PMID: 30241340

Novel Methylselenoesters Induce Programed Cell Death Via Entosis in Pancreatic Cancer Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Sep 23
PMID 30241340
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Redox active selenium (Se) compounds have gained substantial attention in the last decade as potential cancer therapeutic agents. Several Se compounds have shown high selectivity and sensitivity against malignant cells. The cytotoxic effects are exerted by their biologically active metabolites, with methylselenol (CH₃SeH) being one of the key executors. In search of novel CH₃SeH precursors, we previously synthesized a series of methylselenoesters that were active (GI < 10 µM at 72 h) against a panel of cancer cell lines. Herein, we refined the mechanism of action of the two lead compounds with the additional synthesis of new analogs (ethyl, pentyl, and benzyl derivatives). A novel mechanism for the programmed cell death mechanism for Se-compounds was identified. Both methylseleninic acid and the novel CH₃SeH precursors induced entosis by cell detachment through downregulation of cell division control protein 42 homolog (CDC42) and its downstream effector β1-integrin (CD29). To our knowledge, this is the first time that Se compounds have been reported to induce this type of cell death and is of importance in the characterization of the anticancerogenic properties of these compounds.

Citing Articles

Sphingolipid metabolism and regulated cell death in malignant melanoma.

Yan K, Zhang W, Song H, Xu X Apoptosis. 2024; 29(11-12):1860-1878.

PMID: 39068623 DOI: 10.1007/s10495-024-02002-y.


Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer.

Jin X, Jin W, Tong L, Zhao J, Zhang L, Lin N Acta Pharm Sin B. 2024; 14(7):2815-2853.

PMID: 39027232 PMC: 11252466. DOI: 10.1016/j.apsb.2024.04.020.


Trace elements in pancreatic cancer.

Yanjun Y, Jing Z, Yifei S, Gangzhao G, Chenxin Y, Qiang W Cancer Med. 2024; 13(14):e7454.

PMID: 39015024 PMC: 11252496. DOI: 10.1002/cam4.7454.


Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets.

Su C, Mo J, Dong S, Liao Z, Zhang B, Zhu P Cell Commun Signal. 2024; 22(1):71.

PMID: 38279122 PMC: 10811905. DOI: 10.1186/s12964-023-01338-3.


First Generation of Antioxidant Precursors for Bioisosteric Se-NSAIDs: Design, Synthesis, and In Vitro and In Vivo Anticancer Evaluation.

Ramos-Inza S, Aliaga C, Encio I, Raza A, Sharma A, Aydillo C Antioxidants (Basel). 2023; 12(9).

PMID: 37759969 PMC: 10525927. DOI: 10.3390/antiox12091666.


References
1.
Cairns R, Harris I, McCracken S, Mak T . Cancer cell metabolism. Cold Spring Harb Symp Quant Biol. 2011; 76:299-311. DOI: 10.1101/sqb.2011.76.012856. View

2.
Kong B, Qia C, Erkan M, Kleeff J, Michalski C . Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Front Physiol. 2013; 4:246. PMC: 3771311. DOI: 10.3389/fphys.2013.00246. View

3.
Chaitanya G, Steven A, Prakash Babu P . PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 2010; 8:31. PMC: 3022541. DOI: 10.1186/1478-811X-8-31. View

4.
Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M . Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene. 2002; 21(33):5127-34. DOI: 10.1038/sj.onc.1205657. View

5.
Straub B, Rickelt S, Zimbelmann R, Grund C, Kuhn C, Iken M . E-N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells. J Cell Biol. 2011; 195(5):873-87. PMC: 3257573. DOI: 10.1083/jcb.201106023. View